Epigenetic Age and Patient Outcomes after Severe Traumatic Brain Injury
Project Number1R01AG082734-01A1
Former Number1R01AG082734-01
Contact PI/Project LeaderCONLEY, YVETTE P
Awardee OrganizationUNIVERSITY OF PITTSBURGH AT PITTSBURGH
Description
Abstract Text
ABSTRACT
Aging is a risk factor for many chronic conditions including Alzheimer’s disease (AD) and Alzheimer’s disease
related dementias (ADRD) and impacts patient outcomes after traumatic brain injury (TBI). Aging can be
chronologic aging (time since birth) or biological aging that may differ substantially from chronological age for
some individuals, putting them at increased risk (accelerated biological aging) or decreased risk (decelerated
biological aging) for age related conditions including AD and ADRD and poorer recovery from TBI. Epigenetic
age measured using DNA methylation and epigenetic clock computations is one way to quantify biological age.
Another risk factor besides age for ADRD is TBI particularly severe TBI. In our preliminary work we have
developed epigenetic clock based biological age and calculated epigenetic age acceleration from DNA
extracted from serial cerebrospinal fluid (CSF) samples during the acute phase following severe TBI. Our
preliminary work has implicated epigenetic clock based biological age and epigenetic age acceleration during
the acute phase post injury in patient outcomes at 6, 12, and 24 months after severe TBI. We also have
evidence that social deprivation may impact epigenetic age acceleration in patients who have suffered a
severe TBI. Additionally, DNA methylation of the BDNF gene from serial CSF samples could be a biomarker
for patient outcomes after severe TBI, but the role of this biomarker appears to differ depending on the age of
the patient. This project will expand these investigations in a larger cohort of well-characterized severely
injured individuals with severe TBI. Expected results include finding a link between accelerated epigenetic
aging and variation in patient outcomes up to 2 years after severe TBI and that social determinants of health
impact accelerated epigenetic aging in this patient population. Accelerated epigenetic aging could be a useful
biomarker for prognosticating about a patient’s acute and chronic outcomes as well as guiding and monitoring
treatment during the acute and chronic phases after TBI. Knowledge that accelerated epigenetic aging impacts
patient outcomes after severe TBI, and identifying what influences accelerated epigenetic aging in this
population, could also inform treatment developments. Harnessing this knowledge could be beneficial to
patients who have sustained a severe TBI. Knowing that TBI is a risk factor for AD/ADRD, caring for the
severely injured brain with evidence-based interventions could also help mitigate long term sequela after TBI
that includes mitigating risk for AD/ADRD.
Public Health Relevance Statement
Public Health Relevance
Aging is a risk factor for many chronic conditions including Alzheimer’s disease related dementias (ADRD) and
impacts patient outcomes after traumatic brain injury (TBI). Aging can be chronologic aging (time since birth) or
biological aging that may differ substantially from chronological age for some individuals. Another risk factor in
addition to aging for ADRD is TBI particularly severe TBI. This project brings together epigenetic aging and TBI
by investigating the effect of epigenetic age acceleration present acutely after TBI on patient outcomes after
severe TBI. This knowledge could assist in improving long term outcomes for individuals who have suffered a
severe TBI including mitigating risk of ADRD.
No Sub Projects information available for 1R01AG082734-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01AG082734-01A1
Patents
No Patents information available for 1R01AG082734-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01AG082734-01A1
Clinical Studies
No Clinical Studies information available for 1R01AG082734-01A1
News and More
Related News Releases
No news release information available for 1R01AG082734-01A1
History
No Historical information available for 1R01AG082734-01A1
Similar Projects
No Similar Projects information available for 1R01AG082734-01A1